Teijin (3401) Investor Update summary

Strategic direction and vision

• Aims to transform business portfolio, focusing on growth in healthcare, mobility, and infrastructure sectors, with a target of 10%+ ROE by 2028.

• Healthcare vision centers on supporting society through products and services for rare and intractable diseases, prioritizing home healthcare and environmental sustainability.

Healthcare business overview

• Built a leading home healthcare platform in Japan, pioneering oxygen therapy and sleep apnea treatment.

• Core products include HOT devices, CPAP ventilators, and drugs for diabetes and osteoporosis, with top market share in Japan.

• Business model relies on device installation, maintenance, and multidisciplinary support, with a nationwide network.

Growth strategies and operational focus

• Short- to medium-term focus on maximizing profitability of HOT and CPAP, executing a ¥5.0 billion fixed cost reduction, and in-licensing adaptable pharmaceuticals.

• Long-term strategy targets new medical devices, services, and overseas expansion, while avoiding large patent cliffs.

• Business structural shift toward rare diseases and home healthcare, with ongoing product acquisition and portfolio restructuring.